Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Monoamine Oxidase Inhibitors | 3 | 2020 | 22 | 0.530 |
Why?
|
| Receptors, Dopamine D2 | 3 | 2020 | 68 | 0.440 |
Why?
|
| Tetrahydroisoquinolines | 2 | 2021 | 17 | 0.340 |
Why?
|
| Monoamine Oxidase | 2 | 2020 | 31 | 0.340 |
Why?
|
| Flavonoids | 2 | 2020 | 78 | 0.330 |
Why?
|
| Antipsychotic Agents | 3 | 2020 | 68 | 0.310 |
Why?
|
| Drug Design | 3 | 2021 | 154 | 0.300 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 756 | 0.290 |
Why?
|
| Structure-Activity Relationship | 7 | 2020 | 376 | 0.240 |
Why?
|
| Molecular Structure | 6 | 2021 | 467 | 0.220 |
Why?
|
| Haloperidol | 2 | 2012 | 27 | 0.210 |
Why?
|
| Apomorphine | 1 | 2020 | 13 | 0.200 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 56 | 0.190 |
Why?
|
| Pyridines | 1 | 2020 | 113 | 0.190 |
Why?
|
| Cell Proliferation | 3 | 2021 | 1149 | 0.180 |
Why?
|
| Piperazines | 1 | 2020 | 109 | 0.180 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 122 | 0.180 |
Why?
|
| Behavior, Animal | 1 | 2020 | 304 | 0.170 |
Why?
|
| Chalcones | 1 | 2017 | 13 | 0.150 |
Why?
|
| Psoralea | 1 | 2017 | 2 | 0.150 |
Why?
|
| Benzoquinones | 1 | 2017 | 34 | 0.150 |
Why?
|
| Genistein | 1 | 2017 | 41 | 0.150 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2016 | 21 | 0.150 |
Why?
|
| Ibuprofen | 1 | 2016 | 33 | 0.140 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 2 | 2014 | 13 | 0.140 |
Why?
|
| Antiviral Agents | 1 | 2017 | 148 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 112 | 0.140 |
Why?
|
| Microtubules | 1 | 2016 | 113 | 0.140 |
Why?
|
| Acrylamides | 1 | 2014 | 8 | 0.120 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2014 | 13 | 0.120 |
Why?
|
| Dopamine Antagonists | 1 | 2014 | 39 | 0.120 |
Why?
|
| Quinolines | 2 | 2013 | 60 | 0.120 |
Why?
|
| Plant Extracts | 1 | 2017 | 250 | 0.120 |
Why?
|
| Cryptococcus | 1 | 2013 | 4 | 0.120 |
Why?
|
| Quinolinium Compounds | 1 | 2013 | 7 | 0.120 |
Why?
|
| Depression | 1 | 2020 | 664 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2014 | 75 | 0.120 |
Why?
|
| Sulfhydryl Compounds | 1 | 2013 | 46 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2014 | 112 | 0.110 |
Why?
|
| Indoles | 1 | 2014 | 154 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 137 | 0.110 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2012 | 13 | 0.110 |
Why?
|
| Benzothiazoles | 1 | 2012 | 20 | 0.110 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2013 | 103 | 0.110 |
Why?
|
| Cell Line, Tumor | 4 | 2020 | 2128 | 0.110 |
Why?
|
| Azepines | 1 | 2012 | 17 | 0.110 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 53 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2013 | 147 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 794 | 0.100 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2020 | 81 | 0.090 |
Why?
|
| Fungi | 1 | 2010 | 86 | 0.090 |
Why?
|
| Cell Survival | 3 | 2020 | 818 | 0.090 |
Why?
|
| Kinetics | 2 | 2020 | 650 | 0.080 |
Why?
|
| Animals | 7 | 2020 | 14307 | 0.070 |
Why?
|
| Humans | 10 | 2021 | 34853 | 0.070 |
Why?
|
| Binding, Competitive | 2 | 2017 | 103 | 0.070 |
Why?
|
| Ligands | 2 | 2016 | 317 | 0.060 |
Why?
|
| Mice | 3 | 2020 | 5668 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2021 | 107 | 0.050 |
Why?
|
| Crystallography, X-Ray | 1 | 2020 | 237 | 0.050 |
Why?
|
| Catalytic Domain | 1 | 2020 | 97 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 984 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2021 | 1442 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 545 | 0.040 |
Why?
|
| Dopamine Agents | 1 | 2016 | 24 | 0.040 |
Why?
|
| Tubulin | 1 | 2016 | 80 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2016 | 92 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2016 | 309 | 0.030 |
Why?
|
| Receptor, Serotonin, 5-HT2B | 1 | 2014 | 6 | 0.030 |
Why?
|
| Cricetulus | 1 | 2014 | 74 | 0.030 |
Why?
|
| CHO Cells | 1 | 2014 | 107 | 0.030 |
Why?
|
| Interleukin-1alpha | 1 | 2014 | 17 | 0.030 |
Why?
|
| Cricetinae | 1 | 2014 | 217 | 0.030 |
Why?
|
| Indole Alkaloids | 1 | 2013 | 12 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2014 | 91 | 0.030 |
Why?
|
| Basidiomycota | 1 | 2013 | 11 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 42 | 0.030 |
Why?
|
| Vero Cells | 1 | 2013 | 90 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2014 | 140 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 200 | 0.030 |
Why?
|
| Microglia | 1 | 2014 | 152 | 0.030 |
Why?
|
| Butyrophenones | 1 | 2011 | 5 | 0.030 |
Why?
|
| Receptors, Dopamine | 1 | 2011 | 21 | 0.030 |
Why?
|
| Receptors, Serotonin | 1 | 2011 | 21 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2012 | 186 | 0.030 |
Why?
|
| Male | 2 | 2020 | 18870 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2014 | 287 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 9 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 901 | 0.020 |
Why?
|
| Cell Line | 1 | 2014 | 1289 | 0.020 |
Why?
|
| Candidiasis | 1 | 2010 | 85 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2010 | 203 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 281 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 153 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 406 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 1300 | 0.020 |
Why?
|